2024 Prediction from Fran Gregory, Pharm.D., MBA
Fran Gregory, Pharm.D., MBA is the Vice President of Emerging Therapies at Cardinal Health. She thinks 2024 will be an exciting year for cell and gene therapy.
We asked our readers and some members of our editorial advisory board to make predictions for 2024. Here's what Fran Gregory, Pharm.D., MBA said:
“2024 is going to be an exciting year for cell and gene therapy approvals following a strong end to 2023, including new technology types and indications (sickle cell disease, beta-thalassemia, chronic lymphocytic leukemia and tumor- infiltrating lymphocytes therapy in solid tumors). They all necessitate more precise ways of measuring patient outcomes and improved tracking and visibility for all stakeholders.
We’re anticipating increased payer scrutiny and more of a true focus on innovative payment models given multiple new approvals expected between now and 2025, some of which will be approved in much larger patient populations than we’ve seen so far. Biopharma will continue to focus on earlier and more comprehensive launch planning, including market access and channel strategy to anticipate patient access challenges, build stakeholder education and improve patient services programs to address those needs.”
Optimize Your Healthcare Payments with Optum Financial
April 29th 2025Discover how Optum Financial is revolutionizing healthcare payments in our latest whitepaper. Learn how transitioning to electronic payments can reduce administrative costs, streamline claims processing and enhance security.
Read More
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Healthcare hasn't been a priority of the second Trump administration so far, panelists at the Asembia agreed. Medicaid may loom large, though, as the administration and congressional Republicans look for ways to slash government spending as a way of offsetting major tax cuts.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
What 5 Managed Care Trends Experts Say You’re Not Watching Closely Enough
April 29th 2025Managed Healthcare Executive asked several experts in healthcare and managed care two share the trends they think the industry is overlooking. From rising costs and data challenges to shifts in how care is delivered, these are the issues that could have a major impact — and deserve a closer look.
Read More
